Gilead, Ipsen build the case for their PBC drugs at EASL

[cafead]

via Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term efficacy and safety.

article source